▼Resmetirom (REZDIFFRA) gegen metabolische Dysfunktion-assoziierte Steatohepatitis (MASH) Das arznei-telegramm informiert - unabhängig. kritisch. anzeigenfrei.

#Resmetirom (REZDIFFRA) gegen metabolische Dysfunktion-assoziierte #Steatohepatitis (MASH)

Erstmals ist ein Mittel zur Behandlung der metabolischen Fettleberhepatitis im Handel, doch ein klinischer Nutzen ist bislang nicht nachgewiesen.

www.arznei-telegramm.com/de/6465/resm...

NASH/MASH Treatment Market Set for Dramatic Growth, Expected to Reach Over $31 Billion by 2033 The global NASH/MASH treatment market is poised for significant expansion, projected to hit $31.76 billion by 2033, driven by obesity and new therapies.

NASH/MASH Treatment Market Set for Dramatic Growth, Expected to Reach Over $31 Billion by 2033 #USA #Austin #NASH_Treatment #MASH_Treatment #Resmetirom

🚨 𝐍𝐨𝐰 𝐨𝐧𝐥𝐢𝐧𝐞 🚨

Our latest article evaluates the budgetary impact of pathways using cT1 versus SoC (liver biopsy or VCTE) to assign suspected #MASH patients to #resmetirom. See the graphical abstract below for an overview of the study.

Click the link for the full article 👉 bit.ly/4g3dLJQ

📗 ICYMI: Editor-in-Chief of Clinical Research, Elliot B. Tapper, MD, FAASLD, shares the latest highlights from Hepatology Communications including articles on #SLD, #MASLD and #ALD, diet, #resmetirom eligibility, and more! View the latest issue online: bit.ly/4oeZ8qE

Video: bit.ly/4odW8KZ

AASLD’s Practice Statement on #MASLD in children is available in #HEPATOLOGY Early View! This important resource builds on our comprehensive MASLD guidance, including #resmetirom updates & other publications shaping the future of clinical care. journals.lww.com/hep/fulltext...

Early returns on my #resmetirom #rezdiffra #MASH patients at 1 year. So far 7/8 patients reasessed with LSM have a 30% or greater reduction. Hopefully we start getting some real world data to complement the open label trial.
#liversky

Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) This study assessed the budget impact of resmetirom as a treatment for adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate-to-advanced liver fibrosis and estimated total co...

🚨 Now online🚨
Discover the budget impact of #resmetirom as a treatment for adults with non-cirrhotic non-alcoholic steatohepatitis with moderate-to-advanced liver fibrosis and estimated total costs for a hypothetical US private payer. Read the article here👉 bit.ly/4iWpfiq
#liverdisease #HEOR

Reviewing MAESTRO-NASH and the implications for hepatology and health systems in implementation/accessibility of Resmetirom - npj Gut and Liver npj Gut and Liver - Reviewing MAESTRO-NASH and the implications for hepatology and health systems in implementation/accessibility of Resmetirom

A new treatment to improve outcomes in #MASLD: #implementation, accessibility, and health system implications of #Resmetirom | npj Gut and #Liver

🚨 New Expert Panel Recomm. Alert 🚨

🔗📗 tinyurl.com/3he6rybk

💡Expert panel shares practical tips on initiating & monitoring #Resmetirom for #MASH with moderate to advanced fibrosis.

@cugastrohep.bsky.social @amergastroassn.bsky.social @aga-cgh.bsky.social

Hello~ Kickstarting the blue sky with an introduction: I am Victoria, currently doing a #PhD at #RijksuniversiteitGroningen #UMCG on #MASLD using #OrganOnChip specifically #LiverOnChip to model #steatotic liver disease and explore #steatohepatisis and interventions e.g. #resmetirom, happy to connect

FDA approves first drug for common form of liver inflamma... The US Food and Drug Administration has approved the firs...

Thank you ⁦@jechristensen⁩ ⁦@WayneEskridge1⁩ and ⁦@CNN⁩ for raising awareness about steatotic liver disease and treatment options w #rezdiffra #resmetirom #livertwitter ⁦@FattyLiverA⁩ ⁦@GlobalLiver⁩ ⁦@KnowledgeNash⁩ https://dir.lat/iWDRK7

Summary of DDI management with #rezdiffra #resmetirom

✅ Rosuvastatin and simvastatin: no more than 20 mg/d
✅ Pravastatin and atorvastatin: no more than 40 mg/d
✅ reduce by 20 mg with clopidrogel
🛑 don’t use with Gemfibrozil and cyclosporine

#livertwitter

#resmetirom

www.jmcp.org/doi/pdf/10.18553/jmcp.20...

#livertwitter among your #MASH patients who would you prioritize #resmetirom for?

#resmetirom is #rezdiffra the first ever @US_FDA approval in the steatotic liver disease space #livertwitter

Tomorrow is the @US_FDA PDUFA date for #resmetirom. Not since #sofosbuvir has a potential drug approval been more anticipated. This has been an arduous process for #MASH therapeutics.
Hoping we take a first step tomorrow. #livertwitter

@EASLedu @EASLnews improvement in MRE and #VCTE at both 100 and 80 mg doses of #resmetirom limitations include low fibrosis burden in participants. AE included diarrhea and nausea mostly in the first 12 weeks. #ILC2022

@EASLedu @EASLnews both 80 and 100 mg doses of #resmetirom in MAESTRO-NAFLD1 achieved secondary endpoints #ILC2022

@EASLedu @EASLnews Dr. Steve Harrison @Pinnacle_TX presents data for ph3 #resmetirom MAESTRO-NAFLD1 study. Design shown below #ILC2022

@HepDART dr. Becky Taub: histological improvement in absolute fat reduction % by MRI-PDFF on #resmetirom in ph2 compared to other drugs in development $MDGL #hepdart

@HepDART dr. Martins @Allergan summarizes ph3 trials planned in progress #obeticholicacid #cenicriviroc #aramchol #resmetirom #elafibranor #belapectin #galectin #hepdart